Category

Science

Cardax’s Proprietary Astaxanthin Prodrug (CDX-085) Accumulates in Liver, Reduces Elevated Liver Enzymes, and Attenuates Pathohistological Alterations in a Model of Alcohol-Induced Hepatic Stress

By | Science | No Comments
In collaboration with Dr. Steven Weinman, M.D., Ph.D. (Director of the Liver Center at University of Kansas, Kansas City, Kansas), Cardax evaluated the capacity for a proprietary astaxanthin (ASTX) prodrug (CDX-085) to ameliorate oxidative stress-induced hepatic dysfunction in an animal model of disease. In unstressed mice, an 11-day oral administration of 500mg/kg of CDX-085 to mice delivered high levels of ASTX to plasma and liver and importantly liver mitochondria. Eight weeks of CDX-085 treatment (500mg/kg in chow) significantly reduced systemic oxidative stress in vivo measured as diminished MDA levels (TBAR assay, p=0.005).  To further evaluate ASTX influence on disease states,...
Read More

Astaxanthin (ASTX): a natural, safe, powerful and multi-faceted anti-inflammatory with potential in the treatment of Type 2 Diabetes Mellitus (T2DM) and Insulin Resistance (IR)

By | Science | No Comments
By Timothy J. King, Ph.D., Vice President, Research, and A. David Hieber, Ph.D., Associate Director, Biology Type 2 Diabetes Mellitus (T2DM) T2DM is one of the most common age related diseases both in the U.S. and internationally. In 2012, approximately 29.1 million people in the U.S. were currently diagnosed with Type 2 Diabetes Mellitus (T2DM) in addition to as many as 8.1 million (28%) estimated remaining undiagnosed [1]. In addition, approximately 86 million are pre-diabetic in the U.S. T2DM is the 7th leading cause of death and is also the leading cause of kidney failure in the U.S. As of...
Read More

Astaxanthin ameliorates cartilage damage in experimental osteoarthritis. Huang and Chen.

By | Science | No Comments
By Timothy J. King, Ph.D., Vice President, Research Osteoarthritis Background Osteoarthritis (OA) is the most common form of arthritis, a chronic disease of aging.  Effective and safe long-term treatment for most OA patients is not available, creating a large unmet medical need. The potential market for OA is very large, where it is estimated that more than 150 million middle class people globally suffer from OA.  Symptomatic knee OA alone affects roughly 12% of persons 60 years or older.  The number of people with arthritis is projected to grow substantially, with the CDC estimating that by 2030 more than 67...
Read More

Astaxanthin lowers plasma TAG concentrations and increases hepatic antioxidant gene expression in diet-induced obesity mice. Yang et al.

By | Science | No Comments
By Timothy J. King, Ph.D., Vice President, Research The role of oxidative stress and inflammation in liver injury and liver dysfunction as well as the potential for antioxidants to ameliorate liver disease has been established in both animal models and human trials [Sanchez-Valle et al. 2012; Pacana and Sanyal 2012]. Studies utilizing rodent models of liver disease have also demonstrated the efficacy of astaxanthin (ASTX) in ameliorating liver injury [Kang et al. 2001; Curek et al. 2010]. Earlier this year, Shen et al. extended these observations by publishing the effects of ASTX treatment in mouse models of surgically induced (bile...
Read More